Theravance, Ignyta raise follow-ons

Theravance Biopharma Inc. (NASDAQ:TBPH) and Ignyta Inc. (NASDAQ:RXDX) raised a combined $150 million in follow-ons.

Theravance raised $100.1 million through the sale of 4.8 million shares at $21. The company proposed the offering after market close on Wednesday, when its share price was $23.57; it had hoped to sell 4.3 million shares. Leerink, Evercore ISI, Guggenheim and Baird are underwriters. Theravance and partner Mylan N.V. (NASDAQ:MYL) are conducting three Phase III studies of revefenacin ( TD-4208), an inhaled long-acting muscarinic antagonist (LAMA), to treat chronic obstructive pulmonary disease (COPD). Theravance dipped $0.41 to $20.75 on Friday. ...